PerClot Polysaccharide Hemostatic System
Baxter Healthcare Corporation · Decision date May 19, 2023
What did the FDA approve?
FDA lists this as approval of the PerClot® Absorbable Hemostatic Powder, not a broader change to the whole PerClot® Polysaccharide Hemostatic System. The cited scope is surgical procedures, excluding neurological and ophthalmic use, as an adjunctive hemostatic device for suture line bleeding or capillary, venous and arteriolar bleeding.
The statement gives the intended use only; it does not provide a new indication, trial detail, or evidence summary in this record. It also does not say whether this was a first PMA or a supplement, so the relationship to an earlier PMA cannot be resolved from the supplied fields alone.
FDA approval order statement
Approval for the PerClot Absorbable Hemostatic Powder. The device is indicated in surgical procedures (except neurological and ophthalmic) as an adjunctive hemostatic device to assist when control of suture line bleeding or capillary, venous and arteriolar bleeding by pressure, ligature, and other conventional procedures is ineffective or impractical.
- Regulatory pathway
- Original PMA
- Clinical specialty
- General, Plastic Surgery
- Decision date
- May 19, 2023
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P210036
- Regulatory pathway
- Premarket approval application
- Applicant
- Baxter Healthcare Corporation
- Product code
- LMG
- Decision code
- APPR
- Decision date
- May 19, 2023
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Agent, absorbable hemostatic, non-collagen based.
- Applicant
- Baxter Healthcare Corporation
- Product code
- LMG
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P210036 received
Application receipt date recorded by FDA.
P210036 · FDA decision
APPR
P210036/S010 · Related supplement
PerClot Absorbable Hemostatic Powder Accessory Tips
Timeline entries are records held by MedtechLedger for P210036. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P210036
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Baxter Healthcare Corporation | PMA supplement | Nov 7, 2026 | FDA |
Explore the linked device profile
Other records with product code LMG
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
SURGICEL Absorbable HemostatsN12159/S132 | ETHICON, Inc. | PMA supplement | Nov 5, 2026 | FDA |
| ETHICON, Inc. | PMA approval | Oct 14, 1960 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Baxter Healthcare Corporation
- Headquarters
- Not reported
- Brand website
- baxter.com
- FDA applicant address
- 25212 W. Illinois Rte. 120, Round Lake, IL, 60073
Sources and methodology
- Original FDA record: P210036
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records